TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01660841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
Study: NCT04865471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Auxiliary liver transplantation and staged hepatectomy
Study: NCT01980173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bakri balloon
Description: Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
Study: NCT04966403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: building strength, enhancing developmental skills, boosting balance, coordination, and postural control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trampoline-based stretch-shortening cycle exercises
Description: muscle strength
Study: NCT00608634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perillyl alcohol
Description: Applied as topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perillyl alcohol
Description: Applied as topical cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied as topical cream
Study: NCT04535986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
Study: NCT01709903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/salmeterol
Description: Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
Study: NCT01941342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBD and Pancreatoduodenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTCD and Pancreatoduodenectomy
Study: NCT03404414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans
Study: NCT01938820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: anti-viral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: anti-viral therapy
Study: NCT02115243

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Study: NCT03606213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENNVAX-GP
Description: PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENNVAX-GP
Description: PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INO-6145
Description: INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INO-9012
Description: The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
Study: NCT01938820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin-α
Description: antiviral and antifibrosis therapy
Study: NCT01709903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to QVA149
Description: Placebo to QVA149 with SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to fluticasone/salmeterol
Description: Placebo to fluticasone/salmeterol with Accuhaler
Study: NCT00940433

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open properitoneal hernia repair
Description: suprapubic retro-inguinal approach
Study: NCT03606213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INO-9012
Description: The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
Study: NCT00940433

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lechtestien hernia repair
Description: onlay mesh repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic transperitoneal approach
Description: intraperitoneal insufflation followed by re-exiting to the hernia site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic totally extraperitoneal approach
Description: avoiding the peritoneum altogether
Study: NCT03606213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INO-9012
Description: The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
Study: NCT01448434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex- vivo cultured adult allogeneic MSCs
Description: Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmalyte-A
Description: Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
Study: NCT03606213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CELLECTRA® 2000
Description: Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CELLECTRA® 2000
Description: Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CELLECTRA® 2000
Description: Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
Study: NCT02336555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8291
Description: MK-8291 oral tablets
Study: NCT03541811

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination
Description: Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
Study: NCT02336555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8291
Description: MK-8291 oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablets
Study: NCT03541811

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination
Description: Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Habitual physical activity tracking (accelerometer based)
Description: Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Habitual physical activity tracking (accelerometer based)
Description: Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.
Study: NCT04615858

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genepro Generation 3 Protein
Description: Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
Study: NCT01884987

Intervention type: DRUG
Intervention: GM1
Description: This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
Study: NCT03179540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-operative management
Description: Patients who are eligible and provide informed consent to participate in the trial will undergo non-operative management (i.e., active surveillance for 24 months) according to the schedule outlined in the study protocol.
Study: NCT05041634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IHOPE
Description: Integrating Healthy Habits Optimized by Community Participation and Engagled Learning
Study: NCT02861495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humeral Compression/Distraction (CD) Nail
Description: Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
Study: NCT01222832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacitracin
Description: Bacitracin soaked nasopore sponge
Study: NCT04330235

Intervention type: OTHER
Intervention: Healthy Default Kids' Beverage Policy
Description: The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
Study: NCT03630614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Electronic cigarette without nicotine (ECwN) plus active varenicline tablets
Description: The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
Description: The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
Description: The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
Study: NCT01312428

Intervention type: DEVICE
Group type: OTHER
Intervention: Pelvic Alignment Level (PAL) Instrument
Description: Pelvic Alignment Level Instrument Used

Intervention type: DEVICE
Group type: OTHER
Intervention: No Pelvic Alignment Level (PAL) Instrument
Description: No Pelvic Alignment Level Instrument Used
Study: NCT03143582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running
Description: A 13-week running program where youth run for 30 minutes twice weekly.
Study: NCT01797107

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azasite
Description: Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azasite
Description: Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
Study: NCT03629626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function.
Study: NCT04628559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
Study: NCT04451434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet
Study: NCT00935220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin QD (once daily) for 7 days
Description: dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
Study: NCT03813563

Intervention type: DRUG
Intervention: RL
Description: lactated Ringer's

Intervention type: DRUG
Intervention: RL
Description: lactated Ringer's

Intervention type: DRUG
Intervention: PLA
Description: PlasmaLyte

Intervention type: DRUG
Intervention: PLA
Description: PlasmaLyte
Study: NCT01421290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Knee surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative comparator
Description: Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
Study: NCT01427036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MISS
Description: Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHS
Description: Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate.
Study: NCT01629485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Video Curriculum
Description: A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Video Curriculum
Description: A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Task Mastery Training
Description: Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part Task Mastery Training
Description: Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.